The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form

##STR00001##

to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form

##STR00001##

to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Disclosed are an organic compound based on triazine and benzoxazole and an application thereof in an OLED device. The compound of the present application has a relatively high glass transition temperature and molecular thermal stability, is low in absorption and high in refractive index in the field of visible light, and is capable of effectively improving the light extraction efficiency of an OLED device when applied to a capping layer of the OLED device; with a deep HOMO energy level and high electronic mobility, the compound of the present application can be used as the hole blocking layer or the electron transport layer material, so that the recombination degree of the hole and the electron in the light-emitting layer can be improved, and thus the light-emitting efficiency of the OLED device can be enhanced and the service life of the OLED device can be prolonged.

A phosphoramidochloridate morpholino monomer of the following formula is provided: ##STR00001##

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form

##STR00001##

to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form

##STR00001##

to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Disclosed is a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. Also disclosed is a method for preparing a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. The novel adamantane derivative compound or the like has an excellent anti-androgenic effect.

Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e. substitution of one of the hydrogens by methyl) demonstrated chiral discrimination in proteasome CT-L activity inhibition (the S-enantiomer was 35-40 fold more potent than the R-enantiomer).

The present invention relates to a combination comprising at least an immunocytokine comprising at least a primary binding protein or peptide and a cytokine, fused or conjugated to one another, and a secondary binding molecule capable of binding to at least a section of at least one cytokine comprised in the immunocytokine.

The invention relates to compounds of structural formula I

##STR00001## wherein A, D, and E are independently N or CR.sup.3, G, H, and J are independently N or C, K is N or CH, L is N, NR.sup.3 or CR.sup.3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl, (C.sub.2 to C.sub.9) heteroaryl, and 5-indolyl, wherein each of the said (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl is substituted with at least one R.sup.4a group, and wherein said (C.sub.2 to C.sub.9) heteroaryl is C-attached, and R.sup.2 is selected from the group consisting of

##STR00002##